Compare A O Smith Corp (AOS) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
A O Smith Corp vs BioNTech SE - ADR — how do they compare? A O Smith Corp trades at $63.65 (market cap $8.48B), while BioNTech SE - ADR trades at $92.64 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 2.7× A O Smith Corp's market cap, and A O Smith Corp pays a 2.31% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AOS | BNTX | |
|---|---|---|
Market Cap | $8.48B | $23.31B |
Sector | Industrials | Health |
52-Week High | $80.47 | $119.34 |
52-Week Low | $55.78 | $83.89 |
Enterprise Value | $8.98B | $6.60B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
A. O. Smith Corporation (AOS) trades at $63.98, up 1.57% today, with a bullish technical signal from moving averages and support at $63. Recent Q2 2026 earnings beat estimates at $1.03 per share, driven by North America strength, though net income margins softened to 13.15% in 2025. The company maintains solid profitability with a 27.13% ROE and a $0.36 dividend declared for H2-2026.
Outlook is mixed: analyst consensus targets $67.25 with 33% buy ratings, but Zacks flagged AOS as a strong sell in June 2026. Risks include higher input costs, weak China demand, and competitive pressures. Cash flow turned positive in 2026, yet revenue stagnation around $3.8B warrants caution for growth investors.
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
